Flavoxate
Cholinergic Muscarinic Antagonist — GENITO URINARY SYSTEM AND SEX HORMONES
Also known as: flavoxate HCl, flavoxate hydrochloride, urispas
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Flavoxate is an ofp drug in the Cholinergic Muscarinic Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1970. Its mechanism of action is classified as Cholinergic Muscarinic Antagonists. DrugCentral lists 4 molecular targets, including KCNH2, PDE4A|PDE4B|PDE4C|PDE4D and PDE7A|PDE7B. Recorded indications include Dysuria, Increased Urinary Frequency, Nocturia and Suprapubic pain.
- Approval status: ofp (first approved 1970 by the FDA).
- Drug class: Cholinergic Muscarinic Antagonist.
- Mechanism of action: Cholinergic Muscarinic Antagonists.
- Molecular targets: KCNH2, PDE4A|PDE4B|PDE4C|PDE4D, PDE7A|PDE7B and PDE8A|PDE8B (4 listed in DrugCentral).
- Indications: Dysuria, Increased Urinary Frequency, Nocturia, Suprapubic pain and Urgent desire to urinate and others.
- ATC code: G04BD02 (Drugs for urinary frequency and incontinence).
- Molecular formula: C24H25NO4; molecular weight 391.47 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (7)
- Dysuria
- Increased Urinary Frequency
- Nocturia
- Suprapubic pain
- Urgent desire to urinate
- Urinary incontinence
- Urinary Tract Irritation
Contraindications (6)
- Angle-closure glaucoma
- Gastrointestinal hemorrhage
- Gastrointestinal obstruction
- Paralytic ileus
- Pyloric obstruction
- Urinary tract obstruction
Mechanism & targets
| Mechanism of action (MoA) | Cholinergic Muscarinic Antagonists |
|---|---|
| Established pharmacologic class | Cholinergic Muscarinic Antagonist |
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | Ki 4.70 |
| Phosphodiesterase 4 | PDE4A|PDE4B|PDE4C|PDE4D | inhibitor | — |
| Phosphodiesterase 7 | PDE7A|PDE7B | inhibitor | — |
| Phosphodiesterase 8 | PDE8A|PDE8B | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1970-01-15 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
G04BD02 | GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs for urinary frequency and incontinence |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Soft tissue disorder | 486.8 |
| Pneumonia viral | 326.5 |
| Liver function test abnormal | 286.4 |
| Herpes zoster | 250.4 |
| Leukopenia | 217.4 |
| Arthritis | 195.5 |
| Fibromyalgia | 192.1 |
| Blood cholesterol increased | 186.1 |
| Peripheral swelling | 154.4 |
| Synovitis | 148.1 |
| Oral pain | 145.8 |
| Infection | 122.4 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Flavoxate is on its molecule page.
| Molecular formula | C24H25NO4 |
|---|---|
| Molecular weight | 391.47 g/mol |
| CAS number | 15301-69-6 |
| InChIKey | SPIUTQOUKAMGCX-UHFFFAOYSA-N |
| PubChem CID | 3354 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Flavoxate used for?
DrugCentral lists the following indications for Flavoxate: Dysuria, Increased Urinary Frequency, Nocturia, Suprapubic pain, Urgent desire to urinate, Urinary incontinence and Urinary Tract Irritation.
How does Flavoxate work?
Flavoxate is classified as Cholinergic Muscarinic Antagonists; its molecular targets in DrugCentral include KCNH2, PDE4A|PDE4B|PDE4C|PDE4D (inhibitor), PDE7A|PDE7B (inhibitor) and PDE8A|PDE8B (inhibitor).
When was Flavoxate first approved?
Flavoxate was first approved by the FDA in 1970.
What drug class does Flavoxate belong to?
Flavoxate is in the Cholinergic Muscarinic Antagonist class.
What is the chemical formula of Flavoxate?
Flavoxate has the molecular formula C24H25NO4 and a molecular weight of 391.47 g/mol.
Browse: all drugs starting with F · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1175 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200875 — compound record and bioactivity
- PubChem CID 3354 — chemical identifiers
- DrugBank DB01148 — drug record
- FDA UNII 3E74Y80MEY — substance identity
- DailyMed: FDA labels for Flavoxate — current prescribing information (label search)
- UniProt Q12809 (KCNH2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.